Genmab A (GMAB) Acquisitions (2024)

Genmab A (GMAB) reported Acquisitions of -$1.8 billion for Q4 2024, little changed quarter-over-quarter from -$1.8 billion in Q3 2024.

Genmab A (GMAB) Acquisitions (2024) Analysis & Trends

Genmab A has reported Acquisitions for 1 years, with the latest figure at -$1.8 billion in Q4 2024.

For the quarter ending Q4 2024, Acquisitions changed N/A year-over-year to -$1.8 billion; the trailing twelve-month figure through Jun 2025 stood at -$5.3 billion (changed N/A YoY), and the FY2025 full-year result was -$7.2 billion, changed N/A from the prior year.
Acquisitions for Q4 2024 stood at -$1.8 billion, roughly flat from -$1.8 billion in the prior quarter.
The five-year high for Acquisitions was -$1.8 billion in Q2 2024, with the low at -$1.8 billion in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	-
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Genmab A	48.34 Bn	46.82 Bn	831.00 Mn	-

Download Data